{"id":"https://openalex.org/W79347247","doi":"https://doi.org/10.1097/wnf.0b013e3181342f32","title":"A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease","display_name":"A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease","publication_year":2008,"publication_date":"2008-05-01","ids":{"openalex":"https://openalex.org/W79347247","doi":"https://doi.org/10.1097/wnf.0b013e3181342f32","mag":"79347247","pmid":"https://pubmed.ncbi.nlm.nih.gov/18520981","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4372145"},"language":"en","primary_location":{"id":"doi:10.1097/wnf.0b013e3181342f32","doi":"https://doi.org/10.1097/wnf.0b013e3181342f32","is_oa":false,"landing_page_url":"https://doi.org/10.1097/wnf.0b013e3181342f32","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4372145","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103293863","display_name":"Ninds Net-Pd Investigators","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210110767","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"The NINDS NET-PD Investigators","raw_affiliation_strings":["and reprint requests to Wendy R. Galpern, MD, PhD, National Institute of Neurological Disorders and Stroke/National Institutes of Health, Room 2225, 6001 Executive Blvd, Bethesda, MD 20892; E-mail: [email\u00a0protected]","National Institute of Neurological Disorders and Stroke/National Institutes of Health, Room 2225, 6001 Executive Blvd, Bethesda, MD 20892, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"and reprint requests to Wendy R. Galpern, MD, PhD, National Institute of Neurological Disorders and Stroke/National Institutes of Health, Room 2225, 6001 Executive Blvd, Bethesda, MD 20892; E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"]},{"raw_affiliation_string":"National Institute of Neurological Disorders and Stroke/National Institutes of Health, Room 2225, 6001 Executive Blvd, Bethesda, MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103293863"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210110767"],"apc_list":null,"apc_paid":null,"fwci":5.9387,"has_fulltext":false,"cited_by_count":175,"citation_normalized_percentile":{"value":0.96325144,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"31","issue":"3","first_page":"141","last_page":"150"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13796","display_name":"Neuroprotection in Cerebral Ischemia","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9620000123977661},{"id":"https://openalex.org/keywords/creatine","display_name":"creatine","score":0.9049999713897705},{"id":"https://openalex.org/keywords/minocycline","display_name":"minocycline","score":1.0},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9629999995231628},{"id":"https://openalex.org/keywords/early-parkinson-s-disease","display_name":"early-stage Parkinson's disease","score":0.7450000047683716},{"id":"https://openalex.org/keywords/antiparkinsonian-treatment","display_name":"antiparkinsonian therapy","score":0.8289999961853027},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5690000057220459},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7350000143051147},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.4620000123977661},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C2778275353","wikidata":"https://www.wikidata.org/wiki/Q415336","display_name":"Minocycline","level":3,"score":0.9800822734832764},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7897179126739502},{"id":"https://openalex.org/C2779896295","wikidata":"https://www.wikidata.org/wiki/Q223600","display_name":"Creatine","level":2,"score":0.7877628207206726},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7770950794219971},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7513296604156494},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5762662887573242},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46425798535346985},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.44824913144111633},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4428884983062744},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.32911354303359985},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.12953674793243408},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09663555026054382},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003401","descriptor_name":"Creatine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004185","descriptor_name":"Disability Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008911","descriptor_name":"Minocycline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1097/wnf.0b013e3181342f32","doi":"https://doi.org/10.1097/wnf.0b013e3181342f32","is_oa":false,"landing_page_url":"https://doi.org/10.1097/wnf.0b013e3181342f32","pdf_url":null,"source":{"id":"https://openalex.org/S3349026","display_name":"Clinical Neuropharmacology","issn_l":"0362-5664","issn":["0362-5664","1537-162X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Neuropharmacology","raw_type":"journal-article"},{"id":"pmid:18520981","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18520981","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical neuropharmacology","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:europepmc.org:3334364","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4372145","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4372145","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4372145","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Neuropharmacol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3334364","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4372145","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G3076733794","display_name":"Clinical Center for Neuroprotection in Parkinson Disease","funder_award_id":"U10NS044545","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G5553123255","display_name":"NIH Exploratory Trials - Parkinson's Disease","funder_award_id":"U10NS044555","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G5965909701","display_name":"Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50)","funder_award_id":"P50NS038377","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G7645746913","display_name":"Parkinson's Disease Neuroprotection Clinical Trial","funder_award_id":"U10NS044415","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G8903528567","display_name":"Parkinson's Disease Clinical Trial: Statistical Center","funder_award_id":"U01NS043127","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"},{"id":"https://openalex.org/G989118816","display_name":"Neuroprotection Studies in PD: A Coordinating Center.","funder_award_id":"U01NS043128","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"}],"funders":[{"id":"https://openalex.org/F4320337359","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W95961711","https://openalex.org/W1572230556","https://openalex.org/W1954166865","https://openalex.org/W1972991508","https://openalex.org/W1974800756","https://openalex.org/W2036609824","https://openalex.org/W2062781235","https://openalex.org/W2073839177","https://openalex.org/W2081374761","https://openalex.org/W2091323080","https://openalex.org/W2092838550","https://openalex.org/W2103738800","https://openalex.org/W2114862320","https://openalex.org/W2122094983","https://openalex.org/W2136570995","https://openalex.org/W2145189131","https://openalex.org/W2145337544","https://openalex.org/W2148726772","https://openalex.org/W2339005630","https://openalex.org/W2358364508"],"related_works":["https://openalex.org/W2358364508","https://openalex.org/W2143686723","https://openalex.org/W2088982973","https://openalex.org/W2040757453","https://openalex.org/W2076413986","https://openalex.org/W1909668357","https://openalex.org/W2921312611","https://openalex.org/W2558770301","https://openalex.org/W2621043313","https://openalex.org/W1954166865"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"report":[2],"an":[3],"18-month":[4,170],"follow-up":[5,62,82],"on":[6,30],"creatine":[7,31,90,175],"and":[8,32,67,94,122,135,143,148,176],"minocycline":[9,33,95,149,177,197],"futility":[10,28,55],"study,":[11],"the":[12,41,53,71,140,156,193],"Neuroprotective":[13],"Exploratory":[14],"Trials":[15],"in":[16,38,45,83,99,115,132,139],"Parkinson":[17,46],"Disease,":[18],"Futility":[19],"Study":[20,127],"1":[21],"(NET-PD":[22],"FS-1).":[23],"BACKGROUND:":[24],"The":[25],"NET-PD":[26],"FS-1":[27],"study":[29,72],"found":[34],"neither":[35],"agent":[36],"futile":[37],"slowing":[39],"down":[40],"progression":[42],"of":[43,61,70,81,89,110,117,120,124,137,174,196],"disability":[44],"disease":[47],"(PD)":[48],"at":[49],"12":[50],"months":[51,60,80],"using":[52],"prespecified":[54],"threshold.":[56],"An":[57],"additional":[58],"6":[59,79],"aimed":[63],"to":[64,153,158],"assess":[65],"safety":[66,181],"potential":[68],"interactions":[69],"interventions":[73],"with":[74,101],"antiparkinsonian":[75],"therapy.":[76],"METHODS:":[77],"Additional":[78],"randomized,":[84],"blinded":[85],"phase":[86,171,188],"II":[87,172],"trial":[88,173],"(dosage,":[91,96],"10":[92],"g/d)":[93],"200":[97],"mg/d)":[98],"subjects":[100,138],"early":[102],"PD.":[103],"RESULTS:":[104],"By":[105],"18":[106],"months,":[107],"symptomatic":[108,159],"treatment":[109,128],"PD":[111],"symptoms":[112],"was":[113,129],"required":[114],"61%":[116],"creatine,":[118,141],"62%":[119],"minocycline,":[121,142],"60%":[123],"placebo-treated":[125],"subjects.":[126],"prematurely":[130],"discontinued":[131],"9%,":[133],"23%,":[134],"6%":[136],"placebo":[144],"arms,":[145],"respectively.":[146],"Creatine":[147],"did":[150],"not":[151,179],"seem":[152],"adversely":[154],"influence":[155],"response":[157],"therapy":[160],"nor":[161],"increase":[162],"adverse":[163],"events.":[164],"CONCLUSIONS:":[165],"Data":[166],"from":[167],"this":[168],"small,":[169],"do":[178],"demonstrate":[180],"concerns":[182],"that":[183],"would":[184],"preclude":[185],"a":[186,199],"large,":[187],"III":[189],"efficacy":[190],"trial,":[191],"although":[192],"decreased":[194],"tolerability":[195],"is":[198],"concern.":[200]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":22}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}